Background

In patients with pancreatic cancer, at diagnosis approximately 40-45% have metastatic disease and 40% have a locally advanced tumor with involvement of surrounding vessels or organs. Only 5-25% of all patients are potentially eligible for surgery, the only potential cure. During surgery, approximately 10-20% of the patients are considered unresectable because of unexpected liver metastases, peritoneal carcinomatosis or locally advanced disease. Furthermore, in 24-53% of the patients there is recurrence in the liver after surgery, of which 50% within 6 months, suggesting these liver metastases were already present at the time of surgery. These liver metastases are too small to be detected by routine preoperative ultrasound and contrast-enhanced CT (CETC).


With contrast-enhanced, diffusion-weighted MRI (CE-DW-MRI) we can possibly improve detection of liver metastases, improving staging of pancreatic cancer. Therefore a clinical trial on CE-DW-MRI to detect liver metastases in patients with pancreatic cancer is currently ongoing (the DIA-PANC study). As most of these lesions are not visible on transabdominal ultrasound, it is often not possible to obtain a histopathologic biopsy in in order to prove the presence of liver metastases. Therefore, we want to perform MR-guided liver biopsy in these patients, as the next minimal invasive step, to obtain histopathologic proof of liver metastases.


Liverbiopsy.png


Study

Currently, a pilot feasibility study (META-PANC study, n=20) is ongoing, in which we perform MR-guided liver biopsies under local anaesthesia at the Medical Innovation and Technology Expert Center (MITeC) in patients with liver lesions, visible only on MRI, not on CECT or abdominal ultrasound.

People